A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
Active, not recruiting · NCT05142696 · Registry updated 2026-08-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab | Extensive Stage Small Cell Lung Cancer | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-19 | NCT05142696 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Novartis Pharmaceuticals | 432 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| AdventHealth | Orlando | United States | 29 |
| Fox Chase Cancer Center | Philadelphia | United States | 259 |
| Hackensack University Medical Ctr | Hackensack | United States | 4 |
| St Louis University | St Louis | United States | 3 |
| University Cancer and Blood Center LLC | Athens | United States | 49 |
| University Hospitals of Cleveland | Cleveland | United States | 17 |
| University of Kentucky | Lexington | United States | 98 |